The German Federal Patent Court recently referred a question to the European Court of Justice (CJEU) concerning the interpretation of the term “first authorisation” in Article 3 (d) of the EU Supplementary Protection Certificate Regulation (No. 469/2009) (SPC Regulation). The CJEU has been asked to clarify whether a first authorisation for a veterinary medicinal product also already exists if an authorisation for the use of the same active substance in medicinal products for human use was granted before

Background

The Applicant, a pharmaceutical company, requested the grant of a supplementary protection certificate (SPC) at the German Patent Trademark Office (GPTO) in accordance with the SPC Regulation in relation to a veterinary product with the active ingredient Ciclesonide.

The request was based on the EP 2 934 479 with the title “Ciclesonide for the treatment of airway disease in horses”, which was filed on 18 December 2013.
After conducting clinical studies, the Applicant received a veterinary market authorisation on 30 January 2020 in accordance with Directive 2001/82/EC (on the Community code relating to veterinary medicinal products).

As the veterinary authorisation covered the first use of Ciclesonide as an active ingredient for a veterinary medicinal product, the European Medicines Agency considered it to be a new active ingredient in the application process (Article 3 (2) (a) Regulation (EC) 726/2004, laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency).

Similar requests for grant of SPCs were filed in other European member states, such as Czechia, France and The Netherlands

After filing the SPC request on 30 June 2020 at the GPTO, the competent patent department denied the grant of the SPC in a decision dated 22 May 2023. The decision was based on the fact that, already in 2005, a market authorisation for the treatment of human asthma with the active ingredient “Ciclesonide” was granted to another company.

According to the GPTO, such market authorisation had to be considered the first market authorisation for Ciclesonide. Due to the fact that Article 3 (d) of the SPC Regulation requires that the relevant market authorisation has to be first market authorisation, the SPC request could not be based on the veterinary market authorisation from 2020.

SPCs are an important IP right in the pharmaceutical sector, as they extend the patent protection of the respective product for up to five years. Article 3 of the SPC Regulation stipulates the requirements for the grant of an SPC.

At the time of filing the request for grant of an SPC, the following requirements had to be met:

  1. The product is protected by a basic patent in force.
  2. A valid market authorisation to place the product on the EU market as a medicinal product according to Directive 2001/83/EC (on the Community code relating to medicinal products for human use) or Directive 2001/82/EC (on the Community code relating to veterinary medicinal products) was granted.
  3. The product has not already been the subject of an SPC.
  4. the market authorisation referred to in point b), above, is the first authorisation to place the product on the market as a medicinal product.

Key issues

In its argument, the Applicant asserted (among other things):

  • That Article 3 (b) of the SPC Regulation – to which point d), above, refers regarding the first authorisation – requires an existing authorisation according to Directive 2001/83/EC (on the Community code relating to medicinal products for human use) or Directive 2001/82/EC (on the Community code relating to veterinary medicinal products).
  • Therefore, the first authorisation under the SPC Regulation must be understood in relation to the separate authorisation proceedings (for human or veterinary use), meaning that “first authorisations” for each of human and veterinary uses have to be distinguished.
  • Furthermore, the fact that an active ingredient, which already had a market authorisation as a human medicinal product, is considered a new ingredient under regulatory law when later a market authorisation for veterinary use is granted (Article 3 (2) (a) Regulation (EG) 726/2004, laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency) calls for a distinction to be made between human and veterinary authorisations also under the SPC Regulation.
  • In addition, granting the request for an SPC would be in line with the goal of the SPC Regulation to award long and expensive research and development activities with SPC protection, as the authorisation process for veterinary use requires new, comprehensive and independent clinical studies to be conducted.

The GPTO denied the request by stating that the first authorisation had to be considered in view of the active ingredient and not from the therapeutic use. Although the respective market authorisations were based on different Directives, and an authorisation for a human medicinal product is not an authorisation for a medicinal product, this did not mean that the authorisation from 2005 could not be considered a first authorisation under the SPC Regulation.

The Applicant appealed the decision of the GPTO to the German Federal Patent Court, which stayed the proceedings and referred the question to the CJEU as to which market authorisation is to be considered the first one.

Referral to CJEU

In its decision to refer the case to the CJEU, the German Federal Patent Court took the view that, due to the grant of an SPC in Czechia and non-grant in France and The Netherlands, there was a need for the referral to safeguard uniform interpretation and application of European law.

The German Federal Patent Court’s own view currently favours the position of the Applicant:

  • The Court in particular relied on the different legal requirements for market authorisation for human and veterinary medicinal products.
  • Also, the Court took the view that the Applicant correctly stated that the purpose of the SPC Regulation required that there be a distinction made between human and veterinary market authorisations.
  • The fact that the data received from the application proceedings in accordance with Directive 2001/83/EC (on the Community code relating to medicinal products for human use) can usually not be used in proceedings for the application proceedings of the same active ingredient under Directive 2001/82/EC (on the Community code relating to veterinary medicinal products) further supports the position of the Applicant.

Conclusion

The position taken by the Federal Patent Court in the referral question is generally to be welcomed, as it contributes to closer integration of human and veterinary medical research and provides an incentive for corresponding developments.

For new SPC applications involving a similar factual situation, such applications should not be delayed merely to await the decision of the CJEU because to so could result in losing the possibility of obtaining SPC protection through the passing of time.

Contact